282 related articles for article (PubMed ID: 20971593)
41. Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with beta-cyclodextrin.
Lee PS; Han JY; Song TW; Sung JH; Kwon OS; Song S; Chung YB
Int J Pharm; 2006 Jun; 316(1-2):29-36. PubMed ID: 16574357
[TBL] [Abstract][Full Text] [Related]
42. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin.
Figueiras A; Carvalho RA; Ribeiro L; Torres-Labandeira JJ; Veiga FJ
Eur J Pharm Biopharm; 2007 Sep; 67(2):531-9. PubMed ID: 17451924
[TBL] [Abstract][Full Text] [Related]
43. Flutamide-hydroxypropy-beta-chiyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model.
Zuo Z; Kwon G; Stevenson B; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2000; 3(2):220-7. PubMed ID: 10994035
[TBL] [Abstract][Full Text] [Related]
44. Improvement of Pharmaceutical Properties of Zerumbone, a Multifunctional Compound, Using Cyclodextrin Derivatives.
Hassan MM; Mohammed AFA; Elamin KM; Devkota HP; Ohno Y; Motoyama K; Higashi T; Imai T
Chem Pharm Bull (Tokyo); 2020; 68(11):1117-1120. PubMed ID: 33132380
[TBL] [Abstract][Full Text] [Related]
45. Host-guest inclusion complex of propafenone hydrochloride with α- and β-cyclodextrins: spectral and molecular modeling studies.
Siva S; Thulasidhasan J; Rajendiran N
Spectrochim Acta A Mol Biomol Spectrosc; 2013 Nov; 115():559-67. PubMed ID: 23872014
[TBL] [Abstract][Full Text] [Related]
46. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
47. Inclusion complexation of artemisinin with alpha-, beta-, and gamma-cyclodextrins.
Wong JW; Yuen KH
Drug Dev Ind Pharm; 2003 Oct; 29(9):1035-44. PubMed ID: 14606667
[TBL] [Abstract][Full Text] [Related]
48. Preformulative assessment of preformed complexes of gemfibrozil, with cyclodextrins.
Ain S; Philip B; Pathak K
PDA J Pharm Sci Technol; 2008; 62(4):300-8. PubMed ID: 19174958
[TBL] [Abstract][Full Text] [Related]
49. Solid state characterization of α-tocopherol in inclusion complexes with cyclodextrins.
Lange K; Gierlach-Hładon T
Acta Pol Pharm; 2015; 72(1):21-30. PubMed ID: 25850197
[TBL] [Abstract][Full Text] [Related]
50. [Preparation, identification and inclusion actions of irisquinone hydroxypropyl-beta-cyclodextrin inclusion complex].
Zhang XN; Yan XY; Tang LH; Gong JH; Zhang Q
Yao Xue Xue Bao; 2005 Apr; 40(4):369-72. PubMed ID: 16011270
[TBL] [Abstract][Full Text] [Related]
51. Candesartan cilexetil.
Ardiana F; Lestari ML; Indrayanto G
Profiles Drug Subst Excip Relat Methodol; 2012; 37():79-112. PubMed ID: 22469317
[No Abstract] [Full Text] [Related]
52. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
Sharma US; Balasubramanian SV; Straubinger RM
J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
[TBL] [Abstract][Full Text] [Related]
53. Interaction of naproxen with noncrystalline acetyl beta- and acetyl gamma-cyclodextrins in the solid and liquid state.
Bettinetti G; Mura P; Faucci MT; Sorrenti M; Setti M
Eur J Pharm Sci; 2002 Feb; 15(1):21-9. PubMed ID: 11803128
[TBL] [Abstract][Full Text] [Related]
54. Investigation and physicochemical characterization of clarithromycin-citric acid-cyclodextrins ternary complexes.
Zhang X; Zhang Y; Zhong D; Chen Y; Li S
Drug Dev Ind Pharm; 2007 Feb; 33(2):163-71. PubMed ID: 17454048
[TBL] [Abstract][Full Text] [Related]
55. Inclusion complexes of hydrochlorothiazide and β-cyclodextrin: Physicochemical characteristics, in vitro and in vivo studies.
Mendes C; Buttchevitz A; Kruger JH; Kratz JM; Simões CM; de Oliveira Benedet P; Oliveira PR; Silva MA
Eur J Pharm Sci; 2016 Feb; 83():71-8. PubMed ID: 26687444
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.
Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Ishiguro T; Hirayama F; Uekama K; Otagiri M
J Pharm Sci; 2010 Oct; 99(10):4285-94. PubMed ID: 20737636
[TBL] [Abstract][Full Text] [Related]
57. Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins.
De Gaetano F; Cristiano MC; Paolino D; Celesti C; Iannazzo D; Pistarà V; Iraci N; Ventura CA
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421730
[TBL] [Abstract][Full Text] [Related]
58. Physicochemical characterization of 2-hydroxybenzophenone with β-cyclodextrin in solution and solid state.
Sancho MI; Russo MG; Moreno MS; Gasull E; Blanco SE; Narda GE
J Phys Chem B; 2015 May; 119(18):5918-25. PubMed ID: 25893377
[TBL] [Abstract][Full Text] [Related]
59. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):176-9. PubMed ID: 2337940
[TBL] [Abstract][Full Text] [Related]
60. The effect of mechanical grinding on the formation, crystalline changes and dissolution behaviour of the inclusion complex of telmisartan and β-cyclodextrins.
Borba PA; Pinotti M; Andrade GR; da Costa NB; Olchanheski Junior LR; Fernandes D; de Campos CE; Stulzer HK
Carbohydr Polym; 2015 Nov; 133():373-83. PubMed ID: 26344293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
